Myasthenia Gravis and Thymoma

Myasthenia gravis is an autoimmune disorder in which the body produces antibodies—most often against acetylcholine receptors, and in a distinct subset against MuSK—that disrupt signaling at the neuromuscular junction, causing fluctuating muscle weakness that can become life-threatening when it affects breathing. A significant proportion of patients harbor a thymoma, a tumor of the thymus gland that appears to drive or sustain the aberrant immune response, making accurate tumor classification and the decision to perform thymectomy central concerns in clinical management. Researchers are working to understand why different antibody subtypes produce different patterns of weakness and treatment responses, and whether removing the thymus reliably halts disease progression even in patients without a detectable tumor. Immunotherapy has transformed outcomes, but identifying which patients will achieve stable remission versus requiring lifelong treatment—and how thymoma histology shapes that trajectory—remains an active and unresolved area of investigation.

Works

70,900

Total citations

642,272

Keywords

Myasthenia GravisThymic TumorsAutoantibodiesMuSK AntibodiesThymectomyEpidemiology